BRAF (V600 mutant)

Class

Small-molecule, blood-brain-barrier-penetrant BRAF inhibitor

Pathway

Inhibits mutant BRAF kinase in the MAPK/ERK signaling pathway; designed for superior CNS penetration versus approved BRAF inhibitors

BRAF is a kinase enzyme that operates within the MAPK/ERK pathway, a chain of signaling proteins that relays growth signals from the cell surface to the nucleus, instructing cells to divide. In a subset of cancers, a mutation at position 600 of BRAF (commonly V600E) locks the enzyme in an active state, driving continuous downstream signaling and uncontrolled proliferation independent of normal external cues. BRAF inhibitors are small molecules designed to fit into the mutant enzyme's active site and block this constitutive activity, thereby interrupting the pathway and slowing tumor growth. This mechanism is central to treating melanoma and other cancers harboring BRAF V600 mutations, including tumors that spread to the brain. A recognized limitation of earlier BRAF inhibitors is restricted penetration across the blood-brain barrier, the selective membrane that limits which molecules from the bloodstream reach brain tissue. Because BRAF-mutant cancers frequently metastasize to the central nervous system, compounds engineered for improved brain penetration aim to control tumor growth both systemically and within the brain, addressing a site historically undertreated by conventional inhibitors of this pathway.